Lyell Immunopharma, Inc. (LYEL) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Lyell Immunopharma reported revenue of $36,000, down 41.0% from $61,000 the year before. Net income was -$274.4M (a -762355.6% net margin), or -$16.06 per diluted share. Operating margin was -748344.4%. Operating activities generated -$150.0M of cash, leaving -$150.8M of free cash flow. At fiscal year end, Lyell Immunopharma held $340.1M in total assets against $91.8M in total liabilities, including $60.2M of cash and equivalents.
Open the full interactive Lyell Immunopharma financials → Quarterly statements, key ratios, valuation history and price charts.
Lyell Immunopharma Key Stats
| Share Price | $7.51 |
|---|---|
| Market Cap | $175.5M |
| Revenue YoY Growth | -41.0% |
| 52-Week Range | $7.51 – $38.60 |
| Shares Outstanding | 23.4 million (basic, 2026 Q2) |
Lyell Immunopharma Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $10.7M | $84.7M | $130,000 | $61,000 | $36,000 |
| Operating Income | -$214.8M | -$187.1M | -$247.0M | -$358.8M | -$269.4M |
| Pre-Tax Income | -$250.2M | -$183.1M | -$234.6M | -$343.0M | -$274.4M |
| Income Tax | — | — | — | — | $0 |
| Net Income | -$250.2M | -$183.1M | -$234.6M | -$343.0M | -$274.4M |
| Diluted EPS | -$36.80 | -$14.80 | -$18.60 | -$26.20 | -$16.06 |
Lyell Immunopharma Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $15,000 | $6,000 | $2,000 | $4,000 |
| Net Income | -$38.8M | -$140.7M | -$24.2M | -$44.8M |
| Diluted EPS | -$2.13 | -$8.23 | -$1.10 | -$1.92 |
Lyell Immunopharma Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $293.8M | $123.6M | $145.6M | $105.6M | $60.2M |
| Current Assets | $626.3M | $651.3M | $554.7M | $379.6M | $260.9M |
| Total Assets | $1.13B | $937.6M | $750.0M | $490.9M | $340.1M |
| Current Liabilities | $46.7M | $37.0M | $34.5M | $53.8M | $49.4M |
| Total Liabilities | $197.6M | $104.3M | $95.1M | $108.0M | $91.8M |
| Shareholders' Equity | $929.8M | $833.3M | $655.0M | $382.8M | $248.2M |
Lyell Immunopharma Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$126.2M | -$169.6M | -$163.7M | -$162.4M | -$150.0M |
| Cash From Investing | -$121.6M | -$11.5M | $184.0M | $122.4M | $54.1M |
| Cash From Financing | $401.2M | $10.6M | $1.7M | $1.3M | $50.4M |
| Free Cash Flow | -$191.8M | -$193.8M | -$166.4M | -$162.9M | -$150.8M |
Figures from Lyell Immunopharma's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Lyell Immunopharma financials page for every line item.
Lyell Immunopharma Company Profile
| Ticker | LYEL |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | South San Francisco, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001806952 |
Frequently Asked Questions
What was Lyell Immunopharma's revenue in fiscal 2025?
Lyell Immunopharma (LYEL) reported revenue of $36,000 for fiscal 2025.
What is Lyell Immunopharma's annual revenue history?
Lyell Immunopharma's annual revenue by fiscal year: 2021: $10.7M; 2022: $84.7M; 2023: $130,000; 2024: $61,000; 2025: $36,000.
What was Lyell Immunopharma's net income in fiscal 2025?
Lyell Immunopharma reported net income of -$274.4M for fiscal 2025.
What was Lyell Immunopharma's earnings per share (EPS) in fiscal 2025?
Lyell Immunopharma's diluted EPS was -$16.06 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Lyell Immunopharma generate in fiscal 2025?
Lyell Immunopharma generated -$150.8M of free cash flow in fiscal 2025.
What was Lyell Immunopharma's revenue last quarter?
In its most recent reported quarter (2026 Q2), Lyell Immunopharma reported revenue of $4,000.
How many shares of Lyell Immunopharma are outstanding?
Lyell Immunopharma reported a weighted average of 23.4 million basic shares outstanding in 2026 Q2.
What is Lyell Immunopharma's market cap?
Based on its latest closing price, Lyell Immunopharma (LYEL) has a market capitalization of about $175.5M.
When does Lyell Immunopharma's fiscal year end?
Lyell Immunopharma's fiscal year end, as registered with the SEC, is December 31.
Where is Lyell Immunopharma headquartered?
Lyell Immunopharma lists its business address in South San Francisco, California in its SEC filings.